Objective: To evaluate the use of a Na ؉ /H ؉ exchanger (NHE-1) inhibitor as a cardioprotective adjunct therapy to low-volume resuscitation in two different rat models of traumatic hemorrhagic shock.
S evere hemorrhage from traumatic injury is a major causative factor in almost half of the deaths on the battlefield, especially during the early hours after injury. Among survivors, the high rates of multiple organ system failure impair the outcome. Rapid response and early inter-vention are keys to improving survival after traumatic injury (1) . Resuscitation strategies for severe hemorrhage from traumatic injury typically include the immediate restoration of blood pressure through the use of intravenous fluids. However, results from recent studies suggest that rapid, high-volume replacement during resuscitation often exacerbates bleeding and may result in increased mortality compared with either lowvolume or delayed fluid replacement (2) (3) (4) . Metabolic alterations result from insufficient tissue perfusion during severe traumatic hemorrhage cause energy failure, ion pump failure, metabolic acidosis, and release of ischemic metabolites that stimulates a cascade of inflammatory processes (5) . Using effective pharmacologic agent(s) to optimize the extra-and intracellular milieus during stasis and resuscitation, and to preserve cell viability, represent possible strategies to improve resuscitation outcomes from traumatic hemorrhagic shock. The Na ϩ /H ϩ exchange (NHE-1) activity is an important determinant of the extent of cellular injury (6) . NHE-1 activation induced by intracellular acidosis through a protondependent regulation pathway and by endogenous mediators and oxidant stress leads to tissue injury (7, 8) . Because metabolic acidosis, inflammatory mediators, and oxidant stress are all associated with hemorrhagic shock, it follows that blocking this NHE-1 system could be potentially advantageous for improving shockinduced tissue damage. Consistent with this concept are studies showing that NHE-1 inhibition reduces tissue damage in brain, heart, lung, and vascular tissues in ischemia-reperfusion injury (9, 10) . Benzamide, N-(aminoiminomethyl)-4-[4-(2-furanylcarbonyl)-1-piperazinyl]-3-(methylsulfonyl), methanesulfonate (BIIB513) is a potent selective inhibitor of the widespread so-called housekeeping isoform NHE-1. BIIB513 is eight times more potent than HOE 642 (caripodride) in inhibiting the recovery of cells expressing wild-type NHE-1 from acid load and is approximately 37,000 times more selec-tive toward NHE-1 than NHE-3 (11) . We recently reported that NHE-1 inhibition with BIIB513 attenuates cardiovascular decompensation, delays the onset of hypovolemic circulatory shock, and prevents early death in a graded hypovolemic hemorrhagic shock model in pigs (12) . In this study, we extend our previous findings by evaluating the use of this NHE-1 inhibitor as a cardioprotective adjunct therapy to lowvolume resuscitation in two different rat models of traumatic hemorrhagic shock.
MATERIALS AND METHODS

Animals
All animal studies were approved by the Institutional Animal Care and Use Committee and complied with the Animal Welfare Act. Sprague Dawley male rats weighing 300 to 360 g were used in all experiments. The rats were housed under controlled light/dark conditions and were fed with standard rat food and water ad libitum. All animals were observed daily for general health, and all invasive procedures were performed under aseptic conditions.
Surgical Preparation
Animals were anesthetized with ketamine (40 mg/kg, intramuscular) plus xylazine (10 mg/kg, intramuscular). The left external jugular vein was cannulated with a polyethylene tube (PE-50) for the administration of drugs, vehicle, and other fluids. A PE-50 tube was inserted into the right common carotid artery for the measurement of arterial blood pressure with a Powerlab data acquisition system (AD-Instruments, Colorado Springs, CO). Arterial blood gases were measured during the experiment using a blood gas analyzer (Rapidlab 855, Bayer, Tarrytown, NY). The rats were allowed to breathe spontaneously. Body temperature was maintained between 37°C and 39°C using a heating pad.
Series 1: Pressure-Controlled Hemorrhagic Shock with Femur Fracture in Anesthetized Rats. In the first series of studies, the animals were allowed to stabilize for 20 minutes after surgery. A closed, mid-shaft, fracture of the femoral diaphysis was then induced via a three-point bending technique with controlled local soft tissue damage related to the fracture (13) . The animals remained under anesthesia with infusion of ketamine and xylazine. The animals were then bled to a mean arterial pressure of 40 mm Hg from the carotid artery. Mean arterial pressure was maintained at 40 Ϯ 5 mm Hg for 20 minutes by withdrawal or by reinfusion of the shed blood as necessary, and then followed by: 1) no therapy; 2) 15 mL/kg hetastarch (Hextend: 6% hetastarch in lactated electrolyte injection); 3) 3 mg/kg BIIB513 (in 0.3 mL hetastarch) ϩ 15 mL/kg hetastarch resuscitation over 40 minutes. After 4 hours, the animals who survived received a second infusion of 20 mL/kg hetastarch. The experiment was terminated at 6 hours after initial resuscitation.
At the end of the experiment, the animals were humanely euthanized with pentobarbital overdose, a method that is consistent with the recommendation of the Panel on Euthanasia of the American Veterinary Medical Association. Blood and tissues were collected, and stored at Ϫ80°C for biochemical assays.
Series 2: Volume-Controlled Hemorrhagic Shock in Conscious Rats. To eliminate the interference of anesthetic agents on the cardiovascular response to hemorrhagic shock, volume-controlled hemorrhage was carried out in conscious rats. The animal preparation was the same as described for the first series of experiments with the following exceptions. The rats underwent a laparotomy and closure under anesthesia. They were then allowed to recover from anesthesia (2 hours) and subsequently remain conscious for the rest of the study. Hemorrhage was induced by removing 2.5 mL/100 g blood through carotid artery within 15 minutes and the animals remained hypovolemic for an additional 20 minutes. Animals were then randomly assigned to three study groups: 1) no therapy; 2) 15 mL/kg hetastarch; and 3) 3 mg/kg BIIB513 ϩ 15 mL/kg hetastarch resuscitation over 40 minutes. The rats were returned to individual cage and allowed access to food and water. The experiment was terminated at 24 hours after initial resuscitation.
Biochemical Assay
Enzyme immunoassay kits for tumor necrosis factor (TNF)-␣ (R&D Systems, Minneapolis, MN), soluble intercellular adhesion molecule-1 (sICAM-1) (R&D Systems), and C-reactive protein (CRP) (Life Diagnostics, West Chester, PA) were used to determine the concentrations of these mediators in the plasma. Plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST; Biotron Diagnostics, Hemet, CA), and plasma levels of urea (Bioassay System, Hayward, CA) were determined by using assay kits according to the manufacturer's instructions.
Myeloperoxidase Activity in the Liver
Neutrophil accumulation in the liver was measured by determining myeloperoxidase (MPO) activity according to previously published methods (14) . MPO activity in each sample was determined by measuring the change in absorbance at 460 nm. Each sample was tested in triplicate. One unit of MPO activity is the amount of enzyme that will reduce 1 M peroxide per minute. MPO activity was expressed as units per 100 mg weight of tissue.
Statistical Analysis
All data were reported as means Ϯ SD. Statistical differences were determined by analysis of variance for repeated measures followed by modified Student's t test with Bonferroni correction for multiple comparisons. p values Ͻ0.05 using a two-tailed test were considered significant. The chi-square statistic test was used for survival curves.
Materials
BIIB513 was synthesized by Boehringer Ingelheim Pharma KG, Ingelheim, Germany, and was a gift to the investigator. The dose of BIIB513 used in these studies was selected on the basis of our previous experiments that demonstrated protective effects in rat models of coronary artery ischemic-reperfusion injury (15) and prolonged hemorrhagic shock (12, 16) . Hextend (6% hetastarch in lactated electrolyte injection) was purchased from Hospira, Lake Forest, IL.
RESULTS
Series 1.
A total of 33 animals underwent hemorrhage. Five animals died after femur fracture and hemorrhage but were eliminated before resuscitation. These deaths were attributed to primary injury or irreversible shock. Twenty-eight animals were randomly assigned to three study groups: group I, no therapy, n ϭ 8; group II, resuscitation with hetastarch, n ϭ 12; group III, resuscitation with BIIB513 ϩ hetastarch, n ϭ 10. Total blood losses were similar among groups: group I (2.56 mL/100 g), group II (2.51 mL/100 g), and group III (2.59 mL/100 g). Six additional animals underwent a sham surgical procedure alone.
All animals in the no-therapy group died within 2 hours. Compared with hetastarch infusion alone, the addition of NHE-1 inhibition with BIIB513 improved 6 hour survival (42% in hetastarch group vs. 80% in BIIB513 ϩ hetastarch group) ( Fig. 1A) .
Low-volume fluid resuscitation with hetastarch resulted in an improvement in hemodynamic variables. Mean arterial pressure remained significantly below the baseline values during resuscitation. The addition of NHE-1 inhibition with BIIB513 improved the hemodynamic response to fluid resuscitation markedly during the first 2 hours (Fig. 1B) . Table 1 depicts the blood gas parameters after hemorrhage and resuscitation. There were no differences between groups at baseline. Severe hemorrhage and resuscitation resulted in metabolic impairment. Metabolic acidosis developed in animals receiving low-volume resuscitation with hetastarch as evidenced by a fall in the bicarbonate concentration and base excess. Treatment with BIIB513 increased blood oxygen content and prevented the development of metabolic acidosis.
Hemorrhagic shock and reperfusion resulted in a significant inflammatory response. In animals receiving hetastarch resuscitation alone, plasma levels of TNF-␣, ICAM-1, and CRP were significantly increased, and there was a significant accumulation of neutrophils in the liver tissue (Table 2) . NHE-1 inhibition with BIIB513 reduced plasma levels of TNF-␣, ICAM-1, and CRP and attenuated neutrophil infiltration in the liver, as measured by MPO activity.
Series 2. A total of 40 animals underwent hemorrhage. Seven animals died before implementation of resuscitation. Thirty-three animals were randomly assigned to three study groups: 1) no therapy, n ϭ 6; 2) resuscitation with hetastarch, n ϭ 18; and 3) resuscitation with BIIB513 ϩ hetastarch, n ϭ 9.
All animals in the no-therapy group died within 4 hours after hemorrhage. Compared with hetastarch infusion alone, the addition of NHE-1 inhibition with BIIB513 improved 24 hour survival: 44% in hetastarch group vs. 78% in BIIB513 ϩ hetastarch group ( Fig. 2A) .
Low-volume fluid resuscitation with hetastarch improved hemodynamic variables in conscious rats (Fig. 2B ). Mean arterial pressure was slightly higher in the BIIB513 treatment group during the initial resuscitation. There was no difference at 24 hours in animals that survived the procedures.
Plasma levels of TNF-␣, ICAM-1, and CRP, and MPO in the liver are given in Table 2 . Plasma levels of TNF-␣ were markedly increased in animals receiving hetastarch resuscitation alone and were attenuated in animals receiving additional BIIB513. The acute phase proinflammatory markers, CRP and ICAM-1, were not significantly different among groups. This may reflect the different severity and end point of this model. We also measured plasma levels of hepatic enzymes, ALT (a specific marker for hepatic parenchymal injury) and AST (a nonspecific marker for hepatic injury), as indicators of liver injury. There were marked increases in both ALT (2.9ϫ) and AST (2.8ϫ) at 24 hours after hemorrhagic shock (Table 3) , indicating liver injury. NHE inhibition with BIIB513 significantly reduced ALT levels by 41% (p Ͻ 0.05, Table 3 ) and decreased AST level by 16% (p Ͼ 0.05, not significant). We assessed renal dysfunction by mea-suring the rise in plasma levels of urea (an indicator of impaired excretory function of the kidney and/or increased catabolism). Plasma levels of urea were elevated by 144% at 24 hours after hemorrhagic shock, and BIIB513 treatment reduced urea levels by 23% (p Ͼ 0.05, not significant).
DISCUSSION
Low-volume resuscitation with hypertonic fluid is increasingly being used instead of more aggressive fluid replacement because of the posttreatment insults that occur with high-volume fluid resuscitation (17, 18) . Hextend is a high molecular weight hydroxyethyl starch in buffered electrolyte dextrose solution that is approved by the Food and Drug Administration as a plasma volume ex-pander for the treatment of hypovolemia during elective surgery, and has also been selected for use as a field resuscitant by the U.S. military. Using effective pharmacologic agents to ameliorate ischemiareperfusion injury, protecting the whole organism during stasis and reperfusion could offer logistic advantages for battlefield trauma patients, by enabling evacuation and resuscitative surgery during circulatory shock, followed by delayed resuscitation. Thus, in this study, we used low-volume resuscitation with hetastarch at a standard rate and volume recommended by the U.S. military for field resuscitation in models of combined trauma and shock to study these outcomes and to determine whether NHE-1 inhibition improved these results. Our data show that NHE-1 inhibition facilitated the hemodynamic response to fluid resuscitation, attenuated tissue inflammatory injury and organ dysfunction, and most importantly improved survival.
Although the factors that contribute to the transition from reversible hypovolemia to circulatory collapse are not completely understood, it is likely that ischemia-reperfusion injury is a contributing factor. The metabolic consequences of insufficient tissue perfusion occurring in severe hemorrhage are anaerobic glycolysis with increased production of lactate and hydrogen ions, acidosis, impaired mitochondrial energy production, disturbed ionic homeostasis across cell membranes, and reduced functional capacity of tissue cells (19) . The failure of tissue to maintain intracellular calcium (Ca 2ϩ i ) homeostasis during ischemia and resuscitation results in Ca 2ϩ i overload leading to cell death and tissue necrosis (20) . Central to this is NHE activation during ischemia and reperfusion leading to intracellular Na ϩ (Na ϩ i ) and Ca 2ϩ i overload, through proton-dependent regulation pathway and NHE activation by endogenous mediators and oxidant stress (21, 22) . High Ca 2ϩ i is assumed to be one of the main reasons for ischemic and reperfusion injury including arrhythmias, myocardial contractile dysfunction, stunning, and eventually necrosis (6, 8, 20, 21) . In addition, NHE activation during ischemia and reperfusion is also involved in activation of the inflammatory system, leading to tissue inflammatory injury (22, 23) . Thus, in addition to restoring blood pressure, the resuscitation strategies need to reduce the inflammatory response and organ injury. Our stud- ies address this problem by determining if NHE-1 inhibition improves outcomes. Traumatic death usually occurs in a biphasic manner, with the early increased occurrence rate due to the severity of the insult and a late increased occurrence rate due to multiple organ failure and septic complications. Severe hypovolemia from hemorrhage is a major causative factor in almost half of these deaths, especially during the acute period (Ͻ4 hour) after injury (1, 3) . Our previous work indicated that a primary factor in early deaths is due to cardiovascular decompensation. In a pig model of graded hypovolemia, we show that there is a gradual cardiovascular decompensation depending on the severity of blood loss (12) . In that model, myocardial hypercontracture developed with each step of blood loss, as evidenced by a progressive increase of left ventricular wall thickness and an expected decrease in the left ventricular cavity. We suggested that the development of myocardial hypercontracture results in a reduction in myocardial compliance and cardiac output, which contributes to the cardiovascular decompensation and early deaths. In support of this mechanism, we found that plasma levels of creatine phosphokinase, troponin, interleukin-6, TNF-␣, ALT, AST, urea, and MPO in the organ tissues were not very high in animals that died early, suggesting that these early deaths were probably not the result of multiple organ failure. When BIIB513 was administered during the early stages of hemorrhage, we found that the ischemic myocardial hypercontracture and cardiovascular decompensation were attenuated, as were the number of early deaths in this model.
These findings are directly applicable to the present study, where early deaths occurred before and after low-volume resuscitation. On resuscitation, the acidic extracellular fluid is washed out, which reactivates NHE, leading to an unfavorably fast restoration of intracellular pH and again to Na ϩ i and Ca 2ϩ i overload (6, 8) , resulting in cardiac dysfunction. Therefore, NHE activation by intracellular acidosis and other factors could be of pathophysiological significance contributing to the transition from reversible hypovolemia to circulatory collapse. In this study, BIIB513 administered before reperfusion facilitated the hemodynamic response to hetastarch resuscitation and improved survival in both the traumatic and soft-tissue hemorrhagic shock models. These results would be consistent with the findings showing that NHE-1 inhibition improves myocardial function and protects against myocardial ischemic-reperfusion injury (6, 8) .
A systemic proinflammatory response has been implicated in the pathogenesis of organ dysfunction and late death after traumatic hemorrhagic shock (24) . The inflammatory response resulting from hemorrhagic shock is characterized by the up-regulation of cytokine expression and accumulation of neutrophils in a variety of tissues (25, 26) . These changes are prominent in the lung, small bowel, and liver and are likely to contribute to end-organ damage and dysfunction after shock (24) . The mechanism by which hemorrhage triggers this inflammatory response is being intensely investigated. Contributing factors include heightened adrenergic activity (26) and systemic release of proinflammatory agents from the gut (27, 28) . Another possibility includes nuclear factor kappa B. Nuclear factor kappa B is an ubiquitous rapid-response transcription factor that modulates gene expression in various inflammatory conditions including hemorrhagic shock (29) . Nuclear factor kappa B activation causes the expression of several inflammatory cytokines and up-regulates adhesion molecules (30) . Our results are consistent with these reports. We found that severe hemorrhage and subsequent resuscitation with hetastarch alone was associated with a significant increase in the plasma level of TNF-␣, ICAM-1, ALT, and CRP, as well as an increase in MPO activity in the liver, findings supportive of a systemic inflammatory response. BIIB513 given at reperfusion reduced the plasma levels of TNF-␣, ICAM-1, CRP, and ALT and attenuated neutrophil infiltration in the liver after traumatic hemorrhagic shock, suggesting a protective effect of BIIB513 in hemorrhage/resuscitationinduced tissue inflammatory injury and organ dysfunction.
There is substantial evidence indicating that NHE regulates inflammatory processes. NHEs regulate the inflammatory functions of various cell types, including endothelial cells, monocytes, macrophages, and neutrophils (25, 31, 32) . NHEs are rapidly activated in response to a variety of inflammatory signals, such as interleukin-1, TNF-␣, interferon-␥, and lipopolysaccharide (33, 34) . The increased activity of NHE-1 contributes to the production of cytokines in macrophages (31) , and NHE blockade inhibits chemokine production and nuclear factor kappa B activation in immunostimulated endothelial cells (25) . Fujiyoshi et al (35) showed that NHE inhibition attenuated traumatic hemorrhage-induced pulmonary permeability and neutrophil sequestration in the lung tissue. BIIB513 has been shown to reduce myocardial infarction through specific protection of cardiomyocytes and attenuation of neutrophil activity (32) . Our results are consistent with these findings.
CONCLUSIONS
In both traumatic (femur injury) and soft-tissue hemorrhagic shock models in rats, NHE-1 inhibition with BIIB513 facilitated the hemodynamic response to fluid resuscitation, attenuated tissue inflammatory injury and organ dysfunction, but most importantly improved survival. In context with our previous work, these data further affirm the therapeutic potential of NHE-1 inhibition after severe traumatic hemorrhagic shock.
